

89 Re 87/PTO 08 NOV 1996

FORM PTO-1390 (REV 5-93)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		223/051	
INTERNATIONAL APPLICATION NO. PCT/CA95/00287		INTERNATIONAL FILING DATE 12 May 1995	U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 08/737446
PRIORITY DATE CLAIMED		12 May 1994	
TITLE OF INVENTION TREATMENT OF DIABETES			
APPLICANT(S) FOR DO/EO/US AMYLIN PHARMACEUTICALS, INC.			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
<p>1 <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input checked="" type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).</p> <p>4 <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))</p> <p>a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).</p> <p>b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau.</p> <p>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US)</p> <p>6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).</p> <p>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))</p> <p>a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).</p> <p>b. <input type="checkbox"/> have been transmitted by the International Bureau.</p> <p>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</p> <p>d. <input checked="" type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p>			
Items 11. to 16. below concern other document(s) or information included:			
<p>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input type="checkbox"/> A FIRST preliminary amendment.</p> <p><input checked="" type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</p> <p>14. <input type="checkbox"/> A substitute specification.</p> <p>15. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>16. <input type="checkbox"/> Other items or information:</p>			

17.1 The following fees are omitted:

Basic National Fee (37 CFR 1.492(a)(1)-(5)):	910.00
Search Report has been prepared by the EPO or JPO.....	\$ 884.00
International preliminary examination fee paid to USPTO (37 CFR 1.482)	\$ 680.00
No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2))..	\$ 750.00
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....	\$ 1,010.00
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4).....	\$ 94.00

ENTER APPROPRIATE BASIC FEE AMOUNT = \$ 910

Surcharge of \$130.00 for furnishing the oath or declaration later than	<input type="checkbox"/> 20	<input type="checkbox"/> 30
months from the earliest claimed priority date (37 CFR 1.492(e)).	\$	

Claims	Number Filed	Number Extra	Rate
Total 19 Claims	19 -20 -	0	X \$22.00 \$ 0.00
Independent Claims	6 -3 -	3	X \$78.00 \$ 240.00
Multiple dependent claims(s) (if applicable)			+ \$ 250.00 \$ 260.00

TOTAL OF ABOVE CALCULATIONS = \$ 1,540.00

Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity statement	\$
must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).	770.00

SUBTOTAL = \$ 770.00

Processing fee of \$130.00 for furnishing the English translation later than	<input type="checkbox"/> 20	<input type="checkbox"/> 30
months from the earliest claimed priority date (37 CFR 1.492(f)).	+ \$	

TOTAL NATIONAL FEE = \$ 770.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be	\$
accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property	+ \$

TOTAL FEES ENCLOSED = \$ 770.00

Amount to be:	\$
refunded	\$
charged	\$

a. A check in the amount of \$ _____ to cover the above fees is enclosed.

b. Please charge my Deposit Account No. 01-0535 in the amount of \$ 770.00 to cover the above fees.
A duplicate copy of this sheet is enclosed.

c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 01-0535. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Bradford J. Duft
Lyon & Lyon, LLP
633 West 5th Street
47th floor
Los Angeles, CA 90071

SIGNATURE

BD

NAME

32,219

REGISTRATION NUMBER

08/737446

Attorney's Docket No. 223/051

IN THE UNITED STATES

RECEIVING OFFICE (RO/US)
 DESIGNATED OFFICE (DO/US)
 ELECTED OFFICE (EO/US)

PCT/CA95/00287	12 May 1995	12 May 1994
INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
<u>TREATMENT OF DIABETES</u>		
TITLE OF INVENTION		
AMYLIN PHARMACEUTICALS, INC.		
APPLICANT(S)		

Box PCT
Assistant Commissioner for Patents
Washington, D.C. 20231

**VERIFIED CERTIFICATION OF EXPRESS MAILING DATE
(INTERNATIONAL APPLICATION (37 CFR 1.10(c))**

I declare that, on November 8, 1996 deposited, with the United States Postal Service, in an envelope "Express Mail, Post Office to Addressee," bearing Label Number RB921444018 US, addressed to the "Assistant Commissioner for Patents, Washington, D.C. 20231," and having an express mail certification that I executed, the following papers:

Transmittal Letter, Verified Statement Claiming Small Entity, unexecuted
copy of Combined Declaration and Power of Attorney, PCT/IPEA/416,
PCT Request, PCT/IB/301, PCT/IB/304, PCT/ISA/220, PCT Demand,
Response to Written Opinion, PCT/IPEA/408, and Published
PCT Application; and return reply postcard


A copy of these papers from the file of this application is attached.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application of any patent issuing thereon.

Cynthia McGarvie

(typed or printed name of person making this verified statement)

Date 11/8/96



Signature of person making this verified statement